With the recent approval of lecanemab for the treatment of Alzheimer’s disease (AD) by the US Food and Drug Administration (FDA), there is now a push for earlier diagnosis and identification of patients at risk of developing AD. Alvaro Pascual-Leone, MD, PhD, Wolk Center for Memory Health, Hebrew SeniorLife & Harvard Medical School, Boston, MA; Linus Health, CMO, presents Linus Health’s digital brain health platform, designed to facilitate the early detection of AD by primary healthcare providers, thus enabling intervention as early as possible. The platform incorporates a number of screening tools that can quickly identify patients with or at risk of developing mild cognitive impairment (MCI) and in doing so, reduce some of the burden on healthcare providers. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
